Showing 1,061 - 1,080 results of 27,468 for search '(( 50 ((mg decrease) OR (a decrease)) ) OR ( 50 ((ns decrease) OR (we decrease)) ))', query time: 0.92s Refine Results
  1. 1061
  2. 1062
  3. 1063
  4. 1064
  5. 1065
  6. 1066
  7. 1067

    Data_Sheet_2_Immunotolerant p50/NFκB Signaling and Attenuated Hepatic IFNβ Expression Increases Neonatal Sensitivity to Endotoxemia.docx by Sarah McKenna (5040047)

    Published 2018
    “…We evaluated the transcriptional regulation and expression of IFNβ in early neonatal (P0) and adult murine models of endotoxemia (IP LPS, 5 mg/kg). …”
  8. 1068

    Data_Sheet_1_Immunotolerant p50/NFκB Signaling and Attenuated Hepatic IFNβ Expression Increases Neonatal Sensitivity to Endotoxemia.PDF by Sarah McKenna (5040047)

    Published 2018
    “…We evaluated the transcriptional regulation and expression of IFNβ in early neonatal (P0) and adult murine models of endotoxemia (IP LPS, 5 mg/kg). …”
  9. 1069
  10. 1070
  11. 1071
  12. 1072
  13. 1073

    Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase by Safiatou T. Coulibaly (816058)

    Published 2015
    “…Importantly, a remarkable effect is also observed in treatments with the anticancer compound cytarabine (AraC), for which a 10,000 fold decrease in IC50 occurred. …”
  14. 1074

    The ATR IR signal decreases with decreasing dilutions of cells. by Allison L. Stelling (392086)

    Published 2013
    “…<p>Shown is a box plot for serial dilutions of a glioblastoma cell suspension. …”
  15. 1075
  16. 1076
  17. 1077
  18. 1078
  19. 1079

    Prognosis and risk factors of chronic kidney disease progression in patients with diabetic kidney disease and non-diabetic kidney disease: a prospective cohort CKD-ROUTE study by Shengnan Chen (3595319)

    Published 2022
    “…The secondary endpoints were all-cause death and the development of cardiovascular disease (CVD) events. We found that DKD patients have a higher risk to develop 50% eGFR decline endpoint (HR:2.30, 95%CI [1.48–3.58], <i>p</i> < 0.001) and KRT endpoint (HR:1.64, 95%CI [1.13–2.37], <i>p</i> < 0.05) than NDKD patients. …”
  20. 1080